Noninvasive Low-cost Biomarkers for Preclinical Diagnosis and Longitudinal Tracking of Alzheimer's Disease Using Sleep and Resting State EEG
Noninvasive Low-cost Biomarkers for Preclinical Diagnosis and Longitudinal Tracking of Alzheimer's Disease Using Sleep and Resting State EEG
批准号:
10177827
负责人:
BRADFORD C DICKERSON
金额:
$81.19万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-01 至 2023-05-31
关键词:
AdhesivesAlzheimer associated neurodegenerationAlzheimer&aposs DiseaseAlzheimer&aposs disease diagnosisAlzheimer’s disease biomarkerAmyloidAmyloid beta-ProteinBiological MarkersBrainBrain regionCategoriesCerebrumCognitiveDataDiagnosisDiagnosticElderlyElectrodesElectroencephalogramElectrophysiology (science)FrequenciesFunctional Magnetic Resonance ImagingFunctional disorderGoldGrantHomeLeadLinkLymphaticMagnetic Resonance ImagingMeasurementMeasuresMonitorNerve DegenerationPatientsPositron-Emission TomographyResearchRestScreening procedureSleepSleep FragmentationsSleep disturbancesStructureSystemThinnessTranslatingWakefulnessbasal forebrainbasecostcost effectivefunctional lossglymphatic systeminsightneuroimagingneurophysiologynon rapid eye movementnovelpre-clinicalprodromal Alzheimer&aposs diseaseprototypescreeningsignal processingsleep spindlesource localizationtool
中文摘要
项目摘要
本研究的目的是开发低成本、非侵入性的脑电生理生物标志物
在临床前和前驱阿尔茨海默病(AD)患者中,
睡眠和静息状态脑电图(EEG)。最近制定的“临床前”诊断标准
和“前驱”AD取决于β-淀粉样蛋白(Aβ)的测量以及脑结构和功能的变化,
是的。不幸的是,这些“黄金标准”生物标志物太昂贵(约3000美元/患者),侵入性或专业化
进行大规模的筛查因此,迫切需要新的具有成本效益的生物标志物,其是严格的,
与临床前AD的既定标准相关。越来越多的人认识到脑震荡是一种...
睡眠和静息状态下的EEG与潜在的AD病理生理学密切相关。公
已知AD痴呆与睡眠动力学紊乱和睡眠振荡改变有关。间隙
大脑Aβ通过大脑的胶质淋巴或“胶质淋巴”系统的作用,
眼动(NREM)睡眠,并且依赖于EEG慢振荡活动。大脑皮层的发电机
睡眠和静息状态EEG振荡,其可以使用源定位来估计,与大脑重叠
在AD中显示皮质变薄和功能连接丧失的区域。这些关系没有
在临床前或前驱AD中进行了广泛研究。因此,我们建议1)描述关系-
睡眠和静息状态EEG定量测量与神经影像学AD双相之间的关系
2)使用这些新的关系以及EEG中已知的AD相关变化,
基于EEG的AD预测因子,以及3)开发一个框架,将这些发现转化为低成本
(as低至20美元),高度可扩展的工具,用于筛选和跟踪临床前和前驱AD。
英文摘要
PROJECT SUMMARY
The objective of this research is to develop low-cost, non-invasive, electrophysiological biomarkers of brain
amyloid and neurodegeneration in patients with Preclinical and Prodromal Alzheimer's disease (AD) using the
sleep and resting state electroencephalogram (EEG). Diagnostic criteria recently developed for “Preclinical”
and “Prodromal” AD hinge upon measurements of beta-amyloid (Aβ) and changes in brain structure and func-
tion. Unfortunately, these “gold standard” biomarkers are too expensive (~$3k/patient), invasive, or specialized
for large-scale screening efforts. Thus, there is urgent need for novel cost-effective biomarkers that are rigor-
ously linked to established criteria for Preclinical AD. There is a growing appreciation that brain oscillations ob-
served in the sleep and resting state EEG are closely associated with underlying AD pathophysiology. It is well
known that AD dementia is associated with disrupted sleep dynamics and altered sleep oscillations. Clearance
of cerebral Aβ through the brain's glial lymphatic or “glymphatic” system occurs specifically during non-rapid
eye movement (NREM) sleep, and is dependent on EEG slow oscillation activity. The cortical generators of
sleep and resting state EEG oscillations, which can be estimated using source localization, overlap with brain
regions that display cortical thinning and loss of functional connectivity in AD. These relationships have not
been extensively studied in preclinical nor prodromal AD. We therefore propose to 1) characterize the rela-
tionship between quantitative measures of sleep and resting state EEG and neuroimaging AD bi-
omarkers, 2) use these novel relationships alongside known AD-related changes in the EEG to develop
EEG-based predictors of AD, and 3) develop a framework for translating these findings into low-cost
(as little as $20), highly-scalable tools for screening and tracking of preclinical and prodromal AD.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1093/sleep/zsac223
发表时间:
2023-01-11
期刊:
Sleep
影响因子:
5.6
作者:
[]
通讯作者:
DOI:
10.1016/j.sleep.2019.06.003
发表时间:
2020
期刊:
Sleep medicine
影响因子:
4.8
作者:
[Thomas,RobertJ, Chen,Shuqiang, Eden,UriT, Prerau,MichaelJ]
通讯作者:
Prerau,MichaelJ
DOI:
10.1213/ane.0000000000004781
发表时间:
2020-11
期刊:
Anesthesia and analgesia
影响因子:
5.7
作者:
[Shao YR, Kahali P, Houle TT, Deng H, Colvin C, Dickerson BC, Brown EN, Purdon PL]
通讯作者:
Purdon PL
Molecular Imaging Biomarkers in Dementia: Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias.
痴呆症的分子成像生物标志物:淀粉样蛋白和 tau PET 成像有助于评估疑似患有阿尔茨海默病或其他痴呆症的患者。
DOI:
--
发表时间:
2020
期刊:
Practical neurology (Fort Washington, Pa.)
影响因子:
--
作者:
[Dickerson,Brad, Atri,Alireza]
通讯作者:
Atri,Alireza
DOI:
10.1371/journal.pcbi.1011395
发表时间:
2023-08
期刊:
PLoS computational biology
影响因子:
4.3
作者:
[]
通讯作者:
共 7 条
Robust detection of atrophy over short intervals in AD and FTLD
-
批准号:10633960
-
项目类别:
-
资助金额:$83.47万
-
财政年份:2023
-
负责人:BRADFORD C DICKERSON
-
依托单位:
ADRC Consortium for Clarity in ADRD Research Through Imaging
-
批准号:10803806
-
项目类别:
-
资助金额:$3080.0万
-
财政年份:2023
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Toward Personalized Prognosis and Outcomes in Primary Progressive Aphasia
-
批准号:10634041
-
项目类别:
-
资助金额:$251.6万
-
财政年份:2023
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Neuromodulation of brain network function in preclinical and prodromal Alzheimer's Disease
-
批准号:10589289
-
项目类别:
-
资助金额:$25.2万
-
财政年份:2023
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Computational psycholinguistic analysis of speech samples in PPA and AD and FTD
-
批准号:10373191
-
项目类别:
-
资助金额:$20.34万
-
财政年份:2022
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Computational psycholinguistic analysis of speech samples in PPA and AD and FTD
-
批准号:10563169
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2022
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Characterizing sleep brain dynamics associated with Alzheimer's disease pathology and progression in humans using EEG source localization and PET
-
批准号:10590969
-
项目类别:
-
资助金额:$187.17万
-
财政年份:2022
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Use of machine learning to quantify cognitive function in AD, FTD, and DLB
-
批准号:10288487
-
项目类别:
-
资助金额:$20.32万
-
财政年份:2021
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Muli-scale Structural Imaging of Alzheimer's Disease Neuropathology and Neurodegeneration
-
批准号:10207104
-
项目类别:
-
资助金额:$46.11万
-
财政年份:2021
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Use of machine learning to quantify cognitive function in AD, FTD, and DLB
-
批准号:10468302
-
项目类别:
-
资助金额:$23.99万
-
财政年份:2021
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Imaging Core
-
批准号:10620686
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2019
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Imaging Core
-
批准号:10378620
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2019
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Neuroimaging of the Vulnerable Brain in Delirium: Alzheimer's and Aging Imaging Markers
-
批准号:10405119
-
项目类别:
-
资助金额:$25.99万
-
财政年份:2018
-
负责人:BRADFORD C DICKERSON
-
依托单位:
A video intervention to improve decision making in early-onset dementia caregivers
-
批准号:10474968
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2018
-
负责人:BRADFORD C DICKERSON
-
依托单位:
A video intervention to improve decision making in early-onset dementia caregivers
-
批准号:10212957
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2018
-
负责人:BRADFORD C DICKERSON
-
依托单位:
A video intervention to improve decision making in early-onset dementia caregivers
-
批准号:9789160
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2018
-
负责人:BRADFORD C DICKERSON
-
依托单位:
The Aging Brain Under General Anesthesia: Neurophysiology, Neuroimaging Biomarkers of Aging and Alzheimer's Disease, and Post-Operative Cognitive Outcomes
-
批准号:10219066
-
项目类别:
-
资助金额:$63.1万
-
财政年份:2017
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Core F - Neuroimaging Core
-
批准号:9251145
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2017
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
-
批准号:10166936
-
项目类别:
-
资助金额:$83.67万
-
财政年份:2017
-
负责人:BRADFORD C DICKERSON
-
依托单位:
Imaging tau, amyloid, and neurodegeneration in PPA
-
批准号:9753727
-
项目类别:
-
资助金额:$85.5万
-
财政年份:2016
-
负责人:BRADFORD C DICKERSON
-
依托单位:
海外基金